This is a video explaining the request by the Coalition for Affordable T-DM1 to use the Crown Use provisions in the UK patents law, in order to grant compulsory licences on the patents relating to the cancer drug T-DM1, marketed by Roche under the brand name Kadcyla. The video was produced and edited by Zack Struver for KEI, and features narration by Merith Basey from UAEM.
Leaked text can be found here.
On 9 October 2015, Wikileaks released the final text of the IP chapter in the Trans-Pacific Partnership. Jamie Love provided comments via twitter.
https://twitter.com/jamie_love
Updated: 9 October 2015
(In the order posted)
On Wednesday, 7 October 2015, the United States of America delivered the following statement on agenda item 12 (Report on the Standing Committee on Copyright and Related Rights). The US expressed support for a broadcasting treaty under a signal-based approach, focused on “unauthorized simultaneous or near-simultaneous retransmission of broadcast signals to the public over any type of platform, including the Internet.”
On copyright limitations and exceptions, the US expressed support for
In 2011, the FDA told the NIH it could use enforcement discretion to permit importation and sale of unregistered drugs
In 2011, in the context of a shortage of Fabrazyme, the FDA told the NIH if they could “in theory” allow Shire to import and sell Replagal, a drug approved for sale in Europe, but not in the United States, as an unregistered biologic substitute. The remedy explored for the Fabrazyme shortage may be the best way to address a different problem, the price gouging associated with the drug Daraprim (generic name: pyrimethamine).
Statement of KEI on announcement that there is a consensus on the Trans Pacific Partnership (TPP) trade agreement
October 5, 2015, 10am, EST
These comments by James Love, KEI Director
On Monday, 5 October 2015, Brazil delivered the following opening statement on behalf of the Group of Latin and the Caribbean Group (GRULAC) at the World Intellectual Property Organization’s (WIPO) General Assembly.
Statement Delivered by the Delegation of Brazil on behalf of GRULAC“Mr President,
1. I have the honor to deliver this statement on behalf of the Latin American and the Caribbean Group (GRULAC).
Seven Members of House of Representatives Send Letter to USTR Calling For Waiver of WTO Patent Rules for LDCs
October 2, 2015
FOR IMMEDIATE RELEASE
CONTACT: Zack Struver
+1 (202) 332-2670
zack.struver@keionline.orgSeven House Members Push U.S. Trade Representative to Support Indefinite Waiver on Pharmaceutical Patents for Least Developed Countries (LDCs)
Press Release: Coalition for Affordable T-DM1 Asks UK Government to grant compulsory licenses on Roche breast cancer drug
Press Release: Coalition for Affordable T-DM1 Asks the UK Government to Employ Crown Use Authority to Lower Price of Expensive Cancer Drug sold by Roche
CONTACT:
Diarmaid McDonald
email: accessdiarmaid@gmail.com
+44.7894.4557.81Susannah Markandya
email: s.markandya@gmail.com
+44.7811.9573.12Zack Struver
email: zack.struver@keionline.org
Cell: +1.914.582.1428
Office: +1.202.332.2670 (between 2:00 PM and 10:00 PM BST)Senator Bernie Sanders Asks USTR to Endorse Waiver of WTO Patent Rules for Least Developed Countries
Knowledge Ecology International Press Release
28 September 2015
FOR IMMEDIATE RELEASE
CONTACT: Zack Struver
+1 (202) 332-2670
zack.struver@keionline.orgSenator Bernie Sanders asks USTR to endorse “indefinite waiver” of WTO requirements to grant drug patents for Least Developed Countries (LDCs)